Image

LucenceINSIGHT® is a multi-cancer early detection (MCED) next generation sequencing test that screens for the signal of up to 50 cancers in 1 blood test.

The test uses Lucence’s amplicon-based mirror barcoding technology to detect circulating tumor DNA (ctDNA), circulating tumor RNA (ctRNA) and viral DNA. It then predicts tumor location with machine learning.

Image
Image

LucenceINSIGHT® Screens For Cancer With High Accuracy.

Image
  • LucenceINSIGHT® reported 100% positive predictive value (PPV) from a prospective real-world cohort of 264 asymptomatic individuals in 2023.3
  • A performance of 81% sensitivity and 99% specificity was reported from a retrospective cohort of 601 patient samples in 2024.1
Image

Boosting Detection with Circulating Tumor RNA (ctRNA) Tumor Markers

ctRNA are cancer signals shed into the blood by living cancer cells.7
The ctRNA tumor marker boost is useful for screening individuals at high-risk:
  • Family history of lung, colon or breast cancer
  • Heavy smokers
ctRNA tumor marker boost is included with LucenceINSIGHT® 50 and available as an optional add-on for LucenceINSIGHT® 5, Women’s 7, and 12.
 

12.5%

Relative Increase in Sensitivity

for detection of lung, colon and breast cancers with ctRNA + ctDNA*

*Sensitivity increase calculated as relative improvement over a ctDNA-only approach, based on an initial training dataset of three cancer types (breast, lung, colon) and independently validated on an internal dataset. Magnitude of increase varies by cancer type (data on file).4

Image

Case Study Based on LucenceINSIGHT® (ctDNA): Colorectal Cancer3

  • A 60 year-old asymptomatic male underwent cancer screening.
  • LucenceINSIGHT® detected RHOA G62E at 0.4% VAF.
  • PET-CT showed right colon focal uptake (right figure) suspicious of malignancy.
  • Colonoscopy confirmed adenocarcinoma.
  • Subsequent surgery for curative intent confirmed Stage III colorectal cancer.
Image

Focal uptake detected in right ascending colon

Disclaimer: The case study is for educational, scientific presentation purposes only, and individual case outcomes and results may vary. The image, case detail, or other descriptions of the case are provided directly by the treating physician/oncologist in a de-identified manner and reproduced with express permission of the treating physician/oncologist.

  • Patient: 60+ year old asymptomatic Southeast Asian male
  • Detected mutation: RHOA G62E at 0.4% VAF
  • Diagnostic workup: PET-CT
  • Final Diagnosis: Stage III colorectal cancer

Focal uptake detected in right ascending colon

See which LucenceINSIGHT® plan is right for your patients

Frequently Asked Questions

Image

References

  1. Poh, J. et al. J. Clin. Oncol. 2024; 42(16): e15042.
  2. Cumulative risk of 43.1% false positives over 14 screening exams from other tumor marker screening methods including chest radiograph, flexible sigmoidoscopy, CA-125, and transvaginal ultrasonography for women, and chest radiograph, flexible sigmoidoscopy, PSA, and DRE for men. (Croswell, J. et al. Ann. Fam. Med. 2009; 7(3): 212–222.)
  3. Tucker, S. et al. Ann. Oncol. 2023; 34: S1625-S1626.
  4. Stejskal P, et al. Mol Cancer 2023; 22(15).
Image
SINGAPORE OFFICE

211 Henderson Rd #04-02
Henderson Industrial Park
Singapore 159552

sales.asean@lucence.com
+65 6592 5102

HONG KONG OFFICE

Suite 1018, Unit 1001, 10/F, Mira Place Tower A
132 Nathan Road
Tsim Sha Tsui, Kowloon, Hong Kong

sales.hk@lucence.com
+852 5182 7199

FOLLOW US

©2025 Lucence Diagnostics Pte Ltd. All rights reserved. All logos and trademarks are the property of Lucence or their respective owners. The information on this site is intended for audiences in Singapore and Hong Kong only.